Evidence map›Paper›PMID 37787634›Full record

ArticleCurrent protocols2023

In-Cell Arrestin-Receptor Interaction Assays.

Chen Zheng, Jonathan A Javitch, Nevin A Lambert, Prashant Donthamsetti, Vsevolod V Gurevich

Open access · greenAbstract read
In one paragraph

Article in Current protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Chen ZhengDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee.
Jonathan A JavitchDepartments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York.
Nevin A LambertDepartment of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, Georgia.
Prashant DonthamsettiDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee.
Vsevolod V GurevichDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee.
Vanderbilt University · USAugusta University · USNew York Psychoanalytic Society and Institute · US

Funding

STRUCTURE/FUNCTION STUDIES OF VISUAL ARRESTINR01EY011500 · NEI · VANDERBILT UNIVERSITY · PI T M Iverson · 1997 to 2026
$12.3M
Structure of the Dopamine D2-Like Receptor Binding SitesR01MH054137 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI JAVITCH, JONATHAN A · 1995 to 2025
$12.0M
Targeted Engineering of Designer Arrestins to Regulate Cell SignalingR35GM122491 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2017 to 2021
$2.6M
Arrestin interactions with non-receptor binding partnersR01GM077561 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2007 to 2015
$2.3M
Conventional and unconventional GPCR-G protein couplingR35GM145284 · NIGMS · AUGUSTA UNIVERSITY · PI Nevin Alan Lambert · 2022 to 2026
$1.8M
Conformational regulation of arrestin-mediated signalingR01GM081756 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2008 to 2011
$1.5M
Regulation of GPCR signaling with receptor-specific arrestinsR01GM109955 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2015 to 2017
$1.1M
Molecular mechanisms of arrestin functionR01GM063097 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2001 to 2004
$982k
Mechanisms of signal bias in arrestinsR21DA043680 · NIDA · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V., IVERSON, T M · 2017 to 2018
$432k
NEI NIH HHS R01 EY011500NIDA NIH HHS R21 DA043680NIGMS NIH HHS R01 GM063097NIGMS NIH HHS R01 GM077561NIGMS NIH HHS R01 GM081756NIGMS NIH HHS R01 GM109955NIGMS NIH HHS R35 GM122491NIGMS NIH HHS R35 GM145284NIH HHS EY011500 (VVG)NIH HHS GM122491NIH HHS GM145284 (NAL)NIH HHS MH54137 (JAJ)NIMH NIH HHS R01 MH054137
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) represent ∼30% of current drug targets. Ligand binding to these receptors activates G proteins and arrestins, which function in different signaling pathways. Given that functionally selective or biased ligands preferentially activate one of these two groups of pathways, they may be superior medications for certain disease states. The identification of such ligands requires robust drug screening assays for both G protein and arrestin activity. This unit describes protocols for assays that monitor reversible arrestin recruitment to GPCRs in living cells using either bioluminescence resonance energy transfer (BRET) or nanoluciferase complementation (NanoLuc). Two types of assays can be used: one configuration directly measures arrestin recruitment to a GPCR fused to a protein tag at its intracellular C-terminus, whereas the other configuration detects arrestin translocation to the plasma membrane in response to activation of an unmodified GPCR. Together, these assays are powerful tools for studying dynamic interactions between GPCRs and arrestins. © 2023 Wiley Periodicals LLC. Basic Protocol 1: Receptor-arrestin BRET assay to measure ligand-induced recruitment of arrestin to receptors Basic Protocol 2: Receptor-arrestin NANOBIT assay to measure ligand-induced recruitment of arrestin to receptors Alternative Protocol 1: BRET assay to measure ligand-induced recruitment of arrestin to the plasma membrane Alternative Protocol 2: NANOBIT assay to measure ligand-induced recruitment of arrestin to the plasma membrane Support Protocol 1: Optimization of polyethylenimine (PEI) concentration for transfection.

Indexed as

ArrestinArrestinsCell MembraneLigandsResearch DesignArrestinArrestinsLigandsarrestinbioluminescence resonance energy transfer (BRET)G protein-coupled receptors (GPCRs)

Identifiers

PMID37787634
PMCPMC10566372
OpenAlexW4387296841

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.